NEWS
News Updates
A New Beginning, a New Journey—Warmly Celebrating the Official Establishment of the Eurasia Huizhi Shanghai Office
Release time:
2021-02-23 09:53
Source:
Due to the company's growth, Eurasia Huizhi (Beijing) Medical Research Co., Ltd. officially established a Shanghai office on February 19, 2021. The Shanghai office is located at Room 616, Building B, Shengnuoya Building, No. 1759 Jinshajiang Road, Putuo District, Shanghai.
A new beginning, a new journey. All employees of Eurasia Huizhi are fully prepared and eager to go all out in the new year, providing pharmaceutical companies with even more professional MA solutions!
About Eurasia Huizhi
Eurasia Huizhi is a Contract Research Organization (CRO) specializing in providing Phase I to IV clinical studies and related technical services for new drug development. The company places great emphasis on building a strong reputation, grounding its work in real medical needs, and leveraging cutting-edge theoretical foundations. With over 500 pharmaceutical project experiences under its belt, the company’s core team boasts more than 10 years of industry experience each. Guided by an ethos of integrity, mutual win-win cooperation, diligence, and professionalism, Eurasia Huizhi is committed to becoming a leader in pharmaceutical MA solutions. Together with pharmaceutical companies, we strive to bring patients hope for recovery in less time and at lower costs.
Recommended Services
2020-09-25
Eurasia Huizhi boasts more than ten Phase I strategic collaboration centers, providing high-quality, specialized resources for early-phase clinical studies of innovative drugs. For each project, our expert medical team drafts initial clinical study protocols, consults with clinical experts in relevant fields, and develops clinically feasible and regulatory-compliant implementation plans. The company has extensive experience in conducting clinical trials for a variety of new drugs, including chemical drugs, traditional Chinese medicines, and biologics. Our services include: 1) Feasibility Assessment: Clinical trial feasibility evaluation, identification of centers/researchers, and center feasibility assessment & qualification review. 2) Medical and Clinical Strategy & Planning: Clinical trial planning & execution, risk identification & management.
2020-09-25
Opinions of the General Office of the State Council on Conducting Evaluations of the Quality and Efficacy Consistency of Generic Drugs (Guobanfa [2016] No. 8) Generic drugs that were approved for marketing prior to the implementation of the new classification system for chemical drug registration—and which have not been approved in accordance with the principle of consistency in quality and efficacy with the originator drugs—must undergo consistency evaluations. The consistency evaluation of generic drugs refers to the phased and batch-wise assessment of the quality consistency of generic drugs already approved for marketing, based on the principle of consistency in quality and efficacy with the originator drugs. In other words, generic drugs must achieve a level of quality and efficacy that is consistent with the originator drugs. The purpose of conducting these consistency evaluations is to ensure that generic drugs are comparable to the originator drugs in terms of both quality and efficacy.
Leave a message for inquiry
Follow us
Address: Room 3008, Building I, Yingkun Century, No. 6 Courtyard, East Road of the Automobile Museum, Fengtai District, Beijing
Phone: +86 10 86229816 Fax: 010-83739030
Email: bd-oyhz@healtech.com.cn (Business Cooperation)
ouyahuizhi-hr@healtech.com.cn (Resume Submission)
Follow the official account
WeChat Official Account
Friendship Links:Beijing Aotekang Pharmaceutical Technology Development Co., Ltd. Suzhou Suhao Biomaterials Technology Co., Ltd. Beijing Dikang Pharmaceutical Investment Management Co., Ltd. Center for Drug Evaluation, National Medical Products Administration National Medical Products Administration
Copyright © Eurasia Huizhi (Beijing) Medical Research Co., Ltd.